HC Wainwright downgrades Traws Pharma to Neutral, sets $1 target
HC Wainwright & Co. analyst Brandon Folkes downgraded Traws Pharma from Buy to Neutral and announced a $1 price target.

*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Brandon Folkes has downgraded Traws Pharma from Buy to Neutral and established a price target of $1. The rating adjustment reflects a revised outlook on the pharmaceutical company's stock performance.
Rating and Price Target Details
The downgrade moves Traws Pharma from a Buy rating to Neutral. Concurrently, the firm set a specific price objective for the shares.
| Metric | Detail |
|---|---|
| Previous Rating | Buy |
| New Rating | Neutral |
| Price Target | $1 |
The announcement was made by Brandon Folkes, an analyst at HC Wainwright & Co.
What specific factors led to the revised outlook on Traws Pharma's stock performance?
How might this downgrade impact investor confidence in Traws Pharma's near-term prospects?
What upcoming clinical or regulatory milestones could influence future analyst ratings?






















